Nicorette^® QuickMist 1 mg spray

• Each 0,07 mL spray contains 1 mg NICOTINE. 

• Sugar free. Contains sweetener: Sucralose, Acesulfame Potassium 

Used for the treatment of tobacco dependence in adults by relief of nicotine withdrawal symptoms, including cravings, during a quit attempt. Permanent cessation of tobacco use is the eventual objective. NICORETTE^® QUICKMIST should preferably be used in conjunction with a behavioural support program.

• After priming, point the spray nozzle as close to the open mouth as possible. Press firmly the top of the dispenser and release one spray into the mouth, avoiding the lips. Subjects should not inhale while spraying to avoid getting spray into the respiratory tract. For best results, do not swallow for a few seconds after spraying. 

• Local adverse effects of administration are similar to those seen with other orally delivered forms. During the first few days of treatment irritation in the mouth and throat may be experienced, and hiccups are particularly common. Tolerance is normal with continued use. 

• Patients should not eat or drink when administering NICORETTE^® QUICKMIST. 

• Behavioural therapy advice and support will normally improve the success rate.  

Subjects should stop smoking completely during the course of treatment with NICORETTE^® QUICKMIST. 

Adults and elderly:

The following usage schedule is recommended for NICORETTE^® QUICKMIST during full treatment (Step I) and during tapering (Step II and Step III). Up to 4 sprays per hour may be used. Do not exceed 2 sprays per dosing episode and do not exceed 64 sprays (4 sprays per hour, over 16 hours) in any 24-hour period. 

Step 1: Weeks 1 - 6

• Use 1 or 2 sprays when cigarettes normally would have been smoked or if cravings emerge. If after a single spray, cravings are not controlled within a few minutes, a second spray should be used. 

• If 2 sprays are required, future doses may be delivered as 2 consecutive sprays. Most smokers will require 1 – 2 sprays every 30 minutes to 1 hour.

Step 2: Weeks 7 - 9

• Start reducing the number of sprays per day. By the end of week 9 subjects should be using HALF the average number of sprays per day that was used in Step I. 

Step 3: Weeks 10 - 12

• Continue reducing the number of sprays per day so that subjects are not using more than 4 sprays per day during week 12.

• When subjects have reduced to 2 – 4 sprays per day, oromucosal spray use should be discontinued.

1. Data on File - Pharmacodynamic effects of nicotine mouthspray and cystisine tablet.

S2 Nicorette^® Quickmist. Contains NICOTINE (1 mg/spray). Contains sweeteners (0,1 mg sucralose and 0,1 mg acesulfame potassium/spray). Reg. No. 50/32.16/0547 

For full prescribing information, refer to the Professional Information approved by the medicines regulatory authority. 

ZA-NI-2400012